Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
About Author
More Stories
Sing when you’re winning: how karaoke in cars heralds the triumph of Chinese firms
RBA interest rates: Reserve Bank of Australia cuts cash rate to 3.85% amid lowering inflation
M&S expects cyber-attack to last into July and cost £300m in lost profits